标题
MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy
作者
关键词
-
出版物
Frontiers in Oncology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-07-09
DOI
10.3389/fonc.2021.703442
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Convection-enhanced drug delivery for glioblastoma: a review
- (2021) Randy S. D’Amico et al. JOURNAL OF NEURO-ONCOLOGY
- p53 dynamics vary between tissues and are linked with radiation sensitivity
- (2021) Jacob Stewart-Ornstein et al. Nature Communications
- The Role of Hypoxia in Glioblastoma Radiotherapy Resistance
- (2021) Agathe L. Chédeville et al. Cancers
- Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges
- (2021) Keenan Piper et al. Frontiers in Oncology
- CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme
- (2021) Simona Daniele et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an 18F-Labeled Analogue of the MDM2 Inhibitor SP-141
- (2021) Satish K. Chitneni et al. Pharmaceuticals
- FLASH and minibeams in radiation therapy: the effect of microstructures on time and space and their potential application to protontherapy
- (2020) Alejandro Mazal et al. BRITISH JOURNAL OF RADIOLOGY
- Carbon Ion Beam Reirradiation in Recurrent High-Grade Glioma
- (2020) Fabian Eberle et al. Cancer Management and Research
- Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
- (2020) Yuan Fang et al. Acta Pharmaceutica Sinica B
- Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold?
- (2020) Joseph D. Wilson et al. Frontiers in Oncology
- Carbon Ion Therapy: A Modern Review of an Emerging Technology
- (2020) Timothy D. Malouff et al. Frontiers in Oncology
- Particle radiation therapy in the management of malignant glioma: Early experience at the Shanghai Proton and Heavy Ion Center
- (2020) Lin Kong et al. CANCER
- Mdm2 – open questions
- (2020) Matthias Dobbelstein et al. CANCER SCIENCE
- MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia
- (2020) Pau Montesinos et al. Future Oncology
- Recent Small-Molecule Inhibitors of the p53–MDM2 Protein–Protein Interaction
- (2020) Anastasia Beloglazkina et al. MOLECULES
- Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer
- (2020) Wen Li et al. Frontiers in Pharmacology
- Enhancing the therapeutic effects of in vitro targeted radionuclide therapy of 3D multicellular tumor spheroids using the novel stapled MDM2/X-p53 antagonist PM2
- (2020) Anja C. L. Mortensen et al. EJNMMI Research
- Recent Synthetic Approaches towards Small Molecule Reactivators of p53
- (2020) Jerson L. Silva et al. Biomolecules
- Management of glioblastoma: State of the art and future directions
- (2020) Aaron C. Tan et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Combined radiation strategies for novel and enhanced cancer treatment
- (2020) Georgios Kareliotis et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- MDM2 inhibition: an important step forward in cancer therapy
- (2020) Marina Konopleva et al. LEUKEMIA
- Anticancer strategies by upregulating p53 through inhibition of its ubiquitination by MDM2
- (2020) Abiodun Anifowose et al. MEDICINAL CHEMISTRY RESEARCH
- A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma
- (2020) Patrik Johansson et al. Cell Reports
- Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics
- (2020) Ainsley Mike Antao et al. Cancers
- Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action
- (2020) Surendra R. Punganuru et al. Cells
- Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges
- (2020) De-Hua Yu et al. Frontiers in Oncology
- FLASH Radiotherapy: Current Knowledge and Future Insights Using Proton-Beam Therapy
- (2020) Jonathan R. Hughes et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Multi-Faceted Effect of Curcumin in Glioblastoma from Rescuing Cell Clearance to Autophagy-Independent Effects
- (2020) Larisa Ryskalin et al. MOLECULES
- Radioresistance in Glioblastoma and the Development of Radiosensitizers
- (2020) Md Yousuf Ali et al. Cancers
- Carbon Ion Radiobiology
- (2020) Walter Tinganelli et al. Cancers
- Molecular Mechanisms of Treatment Resistance in Glioblastoma
- (2020) Alexander Ou et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: effective synergism against human glioblastoma via p53 re-activation
- (2019) C. Sarisozen et al. JOURNAL OF DRUG TARGETING
- YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway
- (2019) Hui Tong et al. Drug Design Development and Therapy
- A Novel Small Molecule p53 Stabilizer for Brain Cell Differentiation
- (2019) Joana D. Amaral et al. Frontiers in Chemistry
- A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
- (2019) Lukasz Skalniak et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
- (2019) Arushi Khurana et al. OncoTargets and Therapy
- The efficacy and toxicity of ATM inhibition in glioblastoma initiating cells-driven tumor models
- (2019) Guido Frosina et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
- (2019) W. Larry Gluck et al. INVESTIGATIONAL NEW DRUGS
- Clinical translation of FLASH radiotherapy: Why and how?
- (2019) Jean Bourhis et al. RADIOTHERAPY AND ONCOLOGY
- Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
- (2019) Justyna Kocik et al. Cancers
- The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy
- (2019) Yao Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The Importance and Clinical Implications of FLASH Ultra-High Dose-Rate Studies for Proton and Heavy Ion Radiotherapy
- (2019) Nicholas W. Colangelo et al. RADIATION RESEARCH
- MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
- (2019) Douglas D. Fang et al. Journal for ImmunoTherapy of Cancer
- MicroRNA-129 Inhibits Glioma Cell Growth by Targeting CDK4, CDK6, and MDM2
- (2019) Atieh Moradimotlagh et al. Molecular Therapy-Nucleic Acids
- Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma
- (2019) Biao Wang et al. Acta Pharmaceutica Sinica B
- The MDM2/MDMX-p53 antagonist PM2 radiosensitizes wild-type p53 tumors
- (2018) Diana Spiegelberg et al. CANCER RESEARCH
- Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
- (2018) Jo Ishizawa et al. CANCER RESEARCH
- An Update on MDMX and Dual MDM2/X Inhibitors
- (2018) Margarida Espadinha et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme
- (2018) Francesco Merlino et al. JOURNAL OF MEDICINAL CHEMISTRY
- The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells GrownIn Vitroand as Orthotopic Xenografts
- (2018) Cindy R. Timme et al. MOLECULAR CANCER THERAPEUTICS
- Efficacy of the MDM2 inhibitor SAR405838 in glioblastoma is limited by poor distribution across the blood-brain barrier
- (2018) Minjee Kim et al. MOLECULAR CANCER THERAPEUTICS
- Cancer Radiosensitizers
- (2018) Hao Wang et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
- (2018) Nam-Gu Her et al. Cell Death & Disease
- Drug Repositioning in Glioblastoma: A Pathway Perspective
- (2018) Sze Kiat Tan et al. Frontiers in Pharmacology
- Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor
- (2018) Sang-Soo Kim et al. OncoImmunology
- The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy
- (2018) Guochao Liao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents
- (2018) Shipeng He et al. JOURNAL OF MEDICINAL CHEMISTRY
- The p53 Pathway in Glioblastoma
- (2018) Ying Zhang et al. Cancers
- Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
- (2018) Anne Berberich et al. CLINICAL CANCER RESEARCH
- A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
- (2017) Maja de Jonge et al. EUROPEAN JOURNAL OF CANCER
- MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
- (2017) Veronica Tisato et al. Journal of Hematology & Oncology
- Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist
- (2017) Haiyan Wang et al. JOURNAL OF NEUROSURGERY
- Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration
- (2017) Paul A. Clark et al. JOURNAL OF NEUROSURGERY
- European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
- (2017) Michael Weller et al. LANCET ONCOLOGY
- The role of image-guided intensity modulated proton therapy in glioma
- (2017) David R. Grosshans et al. NEURO-ONCOLOGY
- Treatment of meningioma and glioma with protons and carbon ions
- (2017) Sebastian Adeberg et al. Radiation Oncology
- MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
- (2017) Audrey Laroche et al. Oncotarget
- Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search
- (2017) Si Chen et al. RSC Advances
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- Dosimetric advantages of proton therapy compared with photon therapy using an adaptive strategy in cervical cancer
- (2016) Agustinus J. A. J. van de Schoot et al. ACTA ONCOLOGICA
- A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors
- (2016) S. Bauer et al. ANNALS OF ONCOLOGY
- The Roles of MDM2 and MDMX in Cancer
- (2016) Orit Karni-Schmidt et al. Annual Review of Pathology-Mechanisms of Disease
- Activation of apoptosis signalling pathways by reactive oxygen species
- (2016) Maureen Redza-Dutordoir et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Discovery of a novel class of highly potent inhibitors of the p53–MDM2 interaction by structure-based design starting from a conformational argument
- (2016) Pascal Furet et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment
- (2016) Lubing Gu et al. CANCER CELL
- Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review
- (2016) Emanuela Teveroni et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Variations in the Processing of DNA Double-Strand Breaks Along 60-MeV Therapeutic Proton Beams
- (2016) Pankaj Chaudhary et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)
- (2016) Farhad Ravandi et al. LEUKEMIA RESEARCH
- MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition
- (2016) Lina S. Schneider et al. Molecular Oncology
- Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing Program
- (2016) Min H. Kang et al. PEDIATRIC BLOOD & CANCER
- Role of Mdm2 and Mdmx in DNA repair
- (2016) Christine M. Eischen Journal of Molecular Cell Biology
- Mdm2 Phosphorylation Regulates Its Stability and Has Contrasting Effects on Oncogene and Radiation-Induced Tumorigenesis
- (2016) Michael I. Carr et al. Cell Reports
- p53 in the DNA-Damage-Repair Process
- (2016) Ashley B. Williams et al. Cold Spring Harbor Perspectives in Medicine
- MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner
- (2016) Felix Y. Feng et al. NEOPLASIA
- Clinical Overview of MDM2/X-Targeted Therapies
- (2016) Andrew Burgess et al. Frontiers in Oncology
- Cellular and molecular portrait of eleven human glioblastoma cell lines under photon and carbon ion irradiation
- (2015) S. Ferrandon et al. CANCER LETTERS
- Targeting the MDM2/MDM4 Interaction Interface as a Promising Approach for p53 Reactivation Therapy
- (2015) Marsha Pellegrino et al. CANCER RESEARCH
- Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
- (2015) M. Andreeff et al. CLINICAL CANCER RESEARCH
- Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas
- (2015) M. Verreault et al. CLINICAL CANCER RESEARCH
- A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
- (2015) Manfred Westphal et al. EUROPEAN JOURNAL OF CANCER
- In vitro and in vivo anti-glioma activity of a chalcone-quinoxaline hybrid
- (2015) Gecioni Loch-Neckel et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Regulation of MDM2 Stability After DNA Damage
- (2015) Jiaqi Li et al. JOURNAL OF CELLULAR PHYSIOLOGY
- A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation
- (2015) Xishan Chen et al. JOURNAL OF CONTROLLED RELEASE
- Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors
- (2015) Philipp Holzer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Resveratrol, a potential radiation sensitizer for glioma stem cells both in vitro and in vivo
- (2015) Long Wang et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors
- (2015) L. R. Werner et al. MOLECULAR CANCER THERAPEUTICS
- The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents
- (2015) J. Canon et al. MOLECULAR CANCER THERAPEUTICS
- Resveratrol sensitizes glioblastoma-initiating cells to temozolomide by inducing cell apoptosis and promoting differentiation
- (2015) HAO LI et al. ONCOLOGY REPORTS
- Which technique for radiation is most beneficial for patients with locally advanced cervical cancer? Intensity modulated proton therapy versus intensity modulated photon treatment, helical tomotherapy and volumetric arc therapy for primary radiation – an intraindividual comparison
- (2015) Simone Marnitz et al. Radiation Oncology
- Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells
- (2015) Simona Daniele et al. Scientific Reports
- Proton beam radiation induces DNA damage and cell apoptosis in glioma stem cells through reactive oxygen species
- (2015) R. Alan Mitteer et al. Scientific Reports
- The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas
- (2015) Hongxiang Wang et al. NEOPLASIA
- Proton Radiobiology
- (2015) Francesco Tommasino et al. Cancers
- Abstract 4638: NVP-CGM097: a novel p53-Mdm2 inhibitor exhibiting potent antitumor activity in mouse models of human cancer
- (2015) Stéphane Ferretti et al. CANCER RESEARCH
- Stress Response of Glioblastoma Cells Mediated by miR-17-5p Targeting PTEN and the Passenger Strand miR-17-3p Targeting MDM2
- (2015) Haoran Li et al. Oncotarget
- MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
- (2015) Anne Y. Saiki et al. Oncotarget
- PI3K/Akt-mediated regulation of p53 in cancer
- (2014) Aswin G. Abraham et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- ARF tumor suppression in the nucleolus
- (2014) Leonard B. Maggi et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice
- (2014) Subhasree Nag et al. BIOMEDICAL CHROMATOGRAPHY
- Regulation of p53 by Mdm2 E3 Ligase Function Is Dispensable in Embryogenesis and Development, but Essential in Response to DNA Damage
- (2014) Laura A. Tollini et al. CANCER CELL
- Ubiquitin-specific protease 2a stabilizes MDM4 and facilitates the p53-mediated intrinsic apoptotic pathway in glioblastoma
- (2014) Chun-Lin Wang et al. CARCINOGENESIS
- A Fluorescent Probe for Imaging p53-MDM2 Protein-Protein Interaction
- (2014) Zhenzhen Liu et al. Chemical Biology & Drug Design
- Double-Edged Swords as Cancer Therapeutics: Novel, Orally Active, Small Molecules Simultaneously Inhibit p53–MDM2 Interaction and the NF-κB Pathway
- (2014) Chunlin Zhuang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Clinical oxygen enhancement ratio of tumors in carbon ion radiotherapy: the influence of local oxygenation changes
- (2014) L. Antonovic et al. JOURNAL OF RADIATION RESEARCH
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
- (2014) Roger Stupp et al. LANCET ONCOLOGY
- Nanoparticles as drug delivery systems
- (2014) Agnieszka Z. Wilczewska et al. Pharmacological Reports
- Angiogenesis and antiangiogenic agents in cervical cancer
- (2014) Silverio Tomao et al. OncoTargets and Therapy
- p53-independent early and late apoptosis is mediated by ceramide after exposure of tumor cells to photon or carbon ion irradiation
- (2013) Gersende Alphonse et al. BMC CANCER
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- (2013) Mark R. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
- (2013) Qingjie Ding et al. JOURNAL OF MEDICINAL CHEMISTRY
- Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence
- (2013) Hongmei Luo et al. LUNG CANCER
- Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor
- (2013) Barbara Costa et al. PLoS One
- Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy
- (2013) Yong S. Chang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Comparison of carbon ion radiotherapy to photon radiation alone or in combination with temozolomide in patients with high-grade gliomas: Explorative hypothesis-generating retrospective analysis
- (2013) Stephanie E. Combs et al. RADIOTHERAPY AND ONCOLOGY
- Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
- (2013) Bryant England et al. TUMOR BIOLOGY
- Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
- (2013) Binh Vu et al. ACS Medicinal Chemistry Letters
- Depression of p53-independent Akt survival signals in human oral cancer cells bearing mutated p53 gene after exposure to high-LET radiation
- (2012) Yosuke Nakagawa et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The p53 circuit board
- (2012) Kelly D. Sullivan et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Diagnosis and treatment in neuro-oncology: an oncological perspective
- (2012) J H Rees BRITISH JOURNAL OF RADIOLOGY
- High and Low LET Radiation Differentially Induce Normal Tissue Damage Signals
- (2012) Maarten Niemantsverdriet et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Trans-membrane peptide therapy for malignant glioma by use of a peptide derived from the MDM2 binding site of p53
- (2012) Sachiko Yamada et al. JOURNAL OF NEURO-ONCOLOGY
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
- (2012) Isabelle Ray-Coquard et al. LANCET ONCOLOGY
- Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway
- (2012) Xiang Zhang ONCOLOGY REPORTS
- Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program
- (2012) Hernan Carol et al. PEDIATRIC BLOOD & CANCER
- p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors
- (2012) Joern Henze et al. PLoS One
- Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization
- (2012) B. Graves et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Comparison of Critical Structure Dose and Toxicity Risks in Patients with Low Grade Gliomas Treated with IMRT versus Proton Radiation Therapy
- (2012) Elizabeth R. Dennis et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts
- (2011) Cyrus Chargari et al. CANCER LETTERS
- Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs
- (2011) Rosa Puca et al. CELL CYCLE
- A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors
- (2011) J. Tabernero et al. CLINICAL CANCER RESEARCH
- Small molecule agents targeting the p53-MDM2 pathway for cancer therapy
- (2011) Weisi Wang et al. MEDICINAL RESEARCH REVIEWS
- Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program
- (2011) Malcolm A. Smith et al. PEDIATRIC BLOOD & CANCER
- Modelling of the oxygen enhancement ratio for ion beam radiation therapy
- (2011) Tatiana Wenzl et al. PHYSICS IN MEDICINE AND BIOLOGY
- Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme
- (2011) Ruth Villalonga-Planells et al. PLoS One
- Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6
- (2010) Christian A Merkel et al. BMC CANCER
- Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA Trial
- (2010) Stephanie E Combs et al. BMC CANCER
- Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: The CINDERELLA trial
- (2010) Stephanie E Combs et al. BMC CANCER
- A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
- (2010) Federico Bernal et al. CANCER CELL
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery
- (2010) Grzegorz M. Popowicz et al. CELL CYCLE
- Nutlins and Ionizing Radiation in Cancer Therapy
- (2010) Gianna Impicciatore et al. CURRENT PHARMACEUTICAL DESIGN
- Regulation of MDM4
- (2010) Michael et al. Frontiers in Bioscience-Landmark
- Puzzling over MDM4–p53 network
- (2010) F. Mancini et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Automated Network Analysis Identifies Core Pathways in Glioblastoma
- (2010) Ethan Cerami et al. PLoS One
- D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms
- (2010) M. Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mdm2 Affects Genome Stability Independent of p53
- (2009) A. Bouska et al. CANCER RESEARCH
- Genetic alterations and signaling pathways in the evolution of gliomas
- (2009) Hiroko Ohgaki et al. CANCER SCIENCE
- Modes of p53 Regulation
- (2009) Jan-Philipp Kruse et al. CELL
- Different Mechanisms of Cell Death in Radiosensitive and Radioresistant P53 Mutated Head and Neck Squamous Cell Carcinoma Cell Lines Exposed to Carbon Ions and X-Rays
- (2009) Mira Maalouf et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Cell Cycle Perturbations and Genotoxic Effects in Human Primary Fibroblasts Induced by Low-energy Protons and X/γ-rays
- (2009) Antonio ANTOCCIA et al. JOURNAL OF RADIATION RESEARCH
- Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
- (2008) Sanjeev Shangary et al. Annual Review of Pharmacology and Toxicology
- High LET radiation enhances apoptosis in mutated p53 cancer cells through Caspase-9 activation
- (2008) Nobuhiro Yamakawa et al. CANCER SCIENCE
- A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis
- (2008) L Weinmann et al. CELL DEATH AND DIFFERENTIATION
- Targeting the MDM2-p53 Interaction for Cancer Therapy
- (2008) S. Shangary et al. CLINICAL CANCER RESEARCH
- The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML
- (2008) K Kojima et al. LEUKEMIA
- Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53
- (2008) S. Supiot et al. MOLECULAR CANCER THERAPEUTICS
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started